7 October 2019 - A Motueka grandmother says the national drug-buying agency is abandoning her on the scrapheap with "inhumane" testing criteria for who can get a new multiple sclerosis drug.

PHARMAC on Monday confirmed it would fund three new medicines it proposed covering in August for lung cancer, breast cancer and multiple sclerosis.

While Multiple Sclerosis New Zealand has welcomed the announcement that the drug Ocrevus will now be publicly funded – it previously cost individuals about $24,000 a year – for the most common form of MS, it's worried more than 600, or 15%, of patients with a different form of the disease will miss out over what it says are "out-dated" criteria.

Read New Zealand Herald article